Healthcare giant Johnson & Johnson has agreed to a proposed $5.5 billion settlement aimed at resolving approximately 76,000 lawsuits alleging that its talc-based baby powder and related products caused ovarian cancer.

According to Reuters, the proposed agreement covers nearly all pending ovarian cancer claims filed in US federal and state courts. However, the settlement will only take effect if 95% of eligible claimants vote in favor of the deal.

If approved, it could bring an end to one of the largest and longest-running product liability disputes in US corporate history.

Why Is Johnson & Johnson Settling?

Johnson & Johnson has consistently maintained that its talc-based products are safe, do not contain asbestos, and do not cause ovarian cancer.

The company says it is pursuing the settlement to avoid prolonged litigation rather than as an admission of liability.

In a statement quoted by Reuters, the company's Vice President of Litigation said the agreement would allow Johnson & Johnson to move beyond years of legal disputes and continue focusing on its healthcare business.

The company expects to pay approximately:

• $3 billion in 2027
• The remaining amount during 2028

Reuters reported that the final payout could exceed $7 billion if additional eligible claimants choose to participate in the settlement.

What Were the Lawsuits About?

The lawsuits alleged that long-term use of Johnson & Johnson's talc-based baby powder and other talc products caused ovarian cancer.

Many plaintiffs also alleged that the products contained asbestos, a known carcinogen.

Johnson & Johnson has consistently denied both allegations, citing scientific studies that it says support the safety of its products.

The company discontinued sales of talc-based Johnson's Baby Powder in the United States in 2020, replacing it with a cornstarch-based formulation.

Why the Settlement Is Significant

If approved, the settlement would resolve the vast majority of existing ovarian cancer lawsuits currently pending against Johnson & Johnson.

Unlike earlier proposals, however, the agreement would apply only to existing claims and would not prevent future claimants from filing new lawsuits if they believe they have legal grounds to do so.

According to Reuters, limiting the agreement to current cases would allow compensation to be distributed more quickly among existing plaintiffs.

The Long Legal Battle

The litigation has continued for more than a decade and has included:

• Numerous jury trials.
• Appeals.
• Scientific evidence challenges.
• Several favorable verdicts for Johnson & Johnson.
• Three unsuccessful bankruptcy-related settlement attempts.

Reuters also reported that a federal judge recently questioned whether individual plaintiffs would be able to establish that talc specifically caused their ovarian cancer, a development viewed as strengthening the company's litigation position.

Despite those legal successes, Johnson & Johnson opted to pursue a broader settlement.

What Was the "Texas Two-Step"?

One of the most closely watched aspects of the litigation involved a legal strategy commonly known as the "Texas Two-Step."

Under this approach, Johnson & Johnson created a subsidiary that filed for bankruptcy with the goal of resolving all talc-related claims through a single bankruptcy process.

The strategy drew criticism from many plaintiffs, who argued that it allowed a financially healthy company to limit its legal exposure through bankruptcy laws.

US courts ultimately rejected all three bankruptcy filings, allowing the lawsuits to continue.

What Happens Next?

The proposed settlement will now be presented to eligible claimants.

If 95% of participating claimants approve the agreement:

• The settlement will become effective.
• Existing lawsuits covered under the agreement will be resolved.
• Compensation payments are expected to begin according to the agreed schedule.

If the required approval threshold is not reached, Johnson & Johnson could continue defending thousands of lawsuits in courts across the United States.

Why This Matters

The proposed settlement represents a major development in one of the largest product liability cases involving a healthcare company. While Johnson & Johnson continues to deny the allegations, the agreement could provide a path to resolving years of litigation if approved by claimants. The outcome may also influence how large-scale mass tort cases are resolved in the future.

Frequently Asked Questions (FAQs)

How much is Johnson & Johnson paying?

The proposed settlement is valued at $5.5 billion, although the final amount could increase depending on claimant participation.

How many lawsuits does the settlement cover?

The agreement covers approximately 76,000 existing ovarian cancer lawsuits in the United States.

Has Johnson & Johnson admitted wrongdoing?

No. The company continues to deny that its talc-based products caused ovarian cancer or contained asbestos and says the settlement is intended to end lengthy litigation.

What is the 95% requirement?

The settlement will only become effective if at least 95% of eligible claimants agree to participate.

Can future lawsuits still be filed?

Yes. According to Reuters, the proposed settlement applies only to existing claims and does not prevent future claimants from filing new lawsuits.